ReviewTherapeutic advances in medical oncology2017
Docetaxel in prostate cancer: a familiar face as the new standard in a hormone-sensitive setting.
Review in Therapeutic advances in medical oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 70 citations in OpenAlex.
- Emerging evidence for sequencing and combining PSMA-based therapies in prostate cancer.Nature reviews. Urology · 2026Review
- MDA-9/Syntenin small molecule inhibitor IVMT-Rx-4 blocks prostate cancer bone metastasis.Pharmacological research · 2026Article
- Proteoglycans in Prostate Cancer Progression and Therapy Resistance.Medicina (Kaunas, Lithuania) · 2025Review
- Exploring tumor dynamics and responses of prostate cancer to IL-27 based treatment combinations through biodynamic imaging and RNA sequencing analyses.Scientific reports · 2025Article
- Docetaxel Administration via Novel Hierarchical Nanoparticle Reduces Proinflammatory Cytokine Levels in Prostate Cancer Cells.Cancers · 2025Article
- PARP-ish: Gaps in Molecular Understanding and Clinical Trials Targeting PARP Exacerbate Racial Disparities in Prostate Cancer.Cancer research · 2024Review
- Genetic Signatures for Distinguishing Chemo-Sensitive from Chemo-Resistant Responders in Prostate Cancer Patients.Current issues in molecular biology · 2024Article
- Role of volumetric parameters obtained fromAnnals of nuclear medicine · 2023Article
- Review
- Treatment Landscape for Metastatic Castrate-Sensitive Prostate Cancer: A Review.Research and reports in urology · 2023Review
- Utilizing two-dimensional monolayer and three-dimensional spheroids to enhance radiotherapeutic potential by combining gold nanoparticles and docetaxel.Cancer nanotechnology · 2023Article
- Investigating PSMA differential expression in canine uroepithelial carcinomas to aid disease-based stratification and guide therapeutic selection.BMC veterinary research · 2022Article
- TRPC3 shapes the ER-mitochondria CaNature communications · 2022Article
- Synergistic effects of natural products in combination with anticancer agents in prostate cancer: A scoping review.Frontiers in pharmacology · 2022Article
- Chemotherapeutic potential of hesperetin for cancer treatment, with mechanistic insights: A comprehensive review.Heliyon · 2022Review
- Real-world evaluation of upfront docetaxel in metastatic castration-sensitive prostate cancer.World journal of clinical oncology · 2021Article
- Chemotherapy-induced peripheral neuropathy in African American cancer survivors: Risk factors and quality of life outcomes.Cancer medicine · 2021Article
- Role of noncoding RNA in drug resistance of prostate cancer.Cell death & disease · 2021Review
- The role of microRNA-572 in the proliferation and chemotherapeutic treatment of prostate cancer.The Journal of international medical research · 2021Article
- The long non-coding RNA GHSROS reprograms prostate cancer cell lines toward a more aggressive phenotype.PeerJ · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The increasing knowledge of prostate cancer is leading to many questions about its natural history and to reconsider conventional therapeutic strategies. Androgen ablation therapy has been the standard therapy in the advanced setting. Although docetaxel has demonstrated increased survival in patients with metastatic prostate cancer who had progressed to hormone treatments, due to its potential toxicity the role of chemotherapy has been relegated to patients who were symptomatic or who had high tumor burden. Several studies have assessed whether docetaxel could have a role in hormone-sensitive disease or even in earlier stages with no distant metastases. In the CHAARTED and STAMPEDE studies, docetaxel provides an unprecedented increase in overall survival (OS). This review summarizes the evidence behind the paradigm shift to strengthening docetaxel as a new standard of treatment that prolongs survival in earlier stages of prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.